Company Filing History:
Years Active: 2022
Title: Innovator Ramona Schlenker: Advancing Therapeutic Strategies in Munich
Introduction
Ramona Schlenker, a pioneering inventor based in Munich, Germany, has made significant strides in the field of biomedicine with her innovative research. With a focus on immunotherapy, she has a unique patent that holds promise for treating various diseases, including cancer and chronic viral infections.
Latest Patents
Ramona holds a patent for her work on fusion proteins of PD-1 and 4-1BB. This invention encompasses fusion proteins that integrate an extracellular domain derived from PD-1 or CD40L at the N-terminus, a transmembrane domain, and an intracellular domain from 4-1BB or CD28 at the C-terminus. Notably, she also explores fusion proteins that place CD28 at the N-terminus and CD40L at the C-terminus. Additionally, the invention includes nucleic acid molecules encoding these fusion proteins, vectors housing such molecules, and host cells containing these vectors. The patent also outlines methods for producing these host cells and discusses pharmaceutical compositions that include the fusion proteins, nucleic acids, vectors, and host cells aimed at combatting diseases associated with PD-1/PD-L2 or CD40 binding.
Career Highlights
Ramona is affiliated with the Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), where she contributes to groundbreaking research that bridges health and environmental science. Her expertise lies in developing therapeutic strategies that harness the immune system to fight off diseases.
Collaborations
Throughout her career, Ramona has collaborated with esteemed colleagues like Elfriede Noessner and Stephan Weisz. This synergy of talent fosters an environment of innovation, enabling advancements in biomedical research and potential therapeutic applications.
Conclusion
Ramona Schlenker stands out as an influential inventor in the realm of fusion proteins and immunology. With her groundbreaking patent and collaborative spirit, she is well-positioned to make significant contributions to the treatment of diseases that challenge current medical paradigms. Her work at Helmholtz Zentrum München continues to pave the way for innovative therapeutic approaches.